The Swiss voice in the world since 1935

Swiss double Covid vaccine order from Pfizer/BioNTech

vaccine
Switzerland has ordered enough to vaccinate the population more than two times over. Keystone / Fazry Ismail

The Swiss government has signed a new deal with Pfizer/BioNTech for another three million vaccine doses, bringing the total number of doses ordered from five companies to nearly 36 million.

The additional doses will be delivered to Switzerland in April, according to the government. When announcing the “good news”, health minister Alain Berset tweeted that “one million (doses) will already be available in the cantons in April, May and June”.

This comes amid concerns about the slow pace of the vaccine rollout. To date, only 1.3 million doses have been delivered and around 3.8% of the population has been fully vaccinated. As a comparison, in Israel, which has about the same population as Switzerland, more than 40% of the population is fully vaccinated.

During a press conference yesterday, Nora Kronig, deputy director of the Federal Office of Public Health, said vaccinations were still progressing according to plan. “We are still confident that by the end of June we will be able to vaccinate anyone who wants to,” Kronig told reporters.

Spreading its purchases

Switzerland has so far bought more than 35 million doses for its population of 8.6 million. These doses are from five manufacturers: Moderna (13.5 million doses), Pfizer/BioNTech (now around 6 million), Oxford/AstraZeneca (around 5.3 million), Curevac (5 million) and Novavax (6 million).

In a statementExternal link, the government said “given that production and availability of vaccines are subject to such great uncertainty, the federal government continues to look into different vaccine technologies from different vaccine manufacturers”. However, it is focusing on mRNA vaccines because they are “proving to be highly effective and well tolerated”. Four out of the five vaccines ordered are mRNA-based.

So far, only the Pfizer and Moderna vaccines have been approved by the Swiss medical regulator Swissmedic. CureVac and Novavax have not yet filed for approval and Oxford/AstraZeneca’s vaccine is still being reviewed. Swissmedic has said that based on the available data, the safety, efficacy and quality of the vaccine could not be conclusively evaluated. It is still awaiting results of large-scale clinical trials from Oxford/AstraZeneca.

Popular Stories

Most Discussed

News

Venice Biennale of Art: death of curator Koyo Kouoh

More

Koyo Kouoh, prominent art world figure, dies aged 58

This content was published on Koyo Kouoh, curator of the 61st International Art Exhibition of La Biennale di Venezia, Biennale Arte 2026, has died, aged 58, it was announced on Saturday.

Read more: Koyo Kouoh, prominent art world figure, dies aged 58
One in 7 Swiss say they have lost money in a cyber scam

More

One in seven Swiss has lost money to cyber scam

This content was published on One in seven adults in Switzerland has fallen victim to a cyber scam, according to a survey published by the SonntagsZeitung newspaper. One-third of victims have lost over CHF1,000 ($1,200).

Read more: One in seven Swiss has lost money to cyber scam
The United States and China kick off their meeting in Geneva

More

United States and China start tariff talks in Geneva

This content was published on The United States and China have started talks in Geneva aiming to de-escalate a dispute that threatens to cut off trade between the world’s two biggest economies and damage the global economy.

Read more: United States and China start tariff talks in Geneva
Berne wants to finalise the declaration with Washington in 2 weeks' time

More

Switzerland and US agree to accelerate tariff talks

This content was published on After a meeting with US ministers in Geneva on Friday, the Swiss president intends to present Washington with a declaration of intent in the next two weeks.

Read more: Switzerland and US agree to accelerate tariff talks

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR